Running head: ASTHMA 1 Asthma and Stepwise Management Michelle A. Orange Walden University NURS – 6521N - Advanced Pharmacology September 20, 2018
ASTHMA 2 Asthma and Stepwise Management Asthma is a universal health problem that affects all people regardless of age. Asthma is a common disease process that can have the potential to be a serious chronic disease. Asthma is a chronic inflammatory disease that is characterized by narrowing and hyperresponsiveness of the airway [Arc17]. Presenting symptoms mimic many disease processes and include wheezing, shortness of breath, chest tightness, cough, and variable expiratory flow [Poc181]. Because asthma is a heterogeneous disease process, health care providers must be able to recognize and distinguish life-threatening symptoms and the stepwise management approach. Asthma consists of two treatment regimens that include long-term control and quick relief. The purpose of this paper is to define the long-term control and quick relief treatments of asthma and incorporate the stepwise approach to asthma treatment and management. Lastly, this paper will explain how the stepwise approach will assist the patient, and the healthcare provider gain control and maintain the asthma disease process.
ASTHMA 3 Quick Relief and Long-Term Control As with any disease process, the drug therapy goal is to lessen or control the symptoms. Asthma control is defined as the extent to which the effects can be seen or have been decreased or removed by patient treatment [Poc181]. As with the management of any patient disease process their personal goals in regards to their treatment and disease process should be acknowledged and evaluated. Quick Relief . Quick-relief medicines control the symptoms of an asthma attack [CDC181]. These are known as “rescue medications,” and the patient must know the importance of keeping the medication accessible at all times. Quick-relief asthma medication is necessary for all patients regardless of age or severity of asthma. An acute exacerbation can be experienced and in varying degrees of severity. Anyone with a diagnosis of asthma requires a short-acting beta 2 adrenergic-agonist bronchodilator (SABA) for quick relief of the symptoms [Arc17].
You've reached the end of your free preview.
Want to read all 9 pages?
- Summer '15